{"id":"NCT03463031","sponsor":"Glenmark Specialty S.A.","briefTitle":"Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)","officialTitle":"A Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-16","primaryCompletion":"2018-11-14","completion":"2018-11-14","firstPosted":"2018-03-13","resultsPosted":"2019-10-08","lastUpdate":"2019-10-08"},"enrollment":446,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis (SAR)"],"interventions":[{"type":"DRUG","name":"GSP 301 NS","otherNames":[]},{"type":"DRUG","name":"GSP 301 Placebo NS","otherNames":[]}],"arms":[{"label":"GSP 301 NS","type":"EXPERIMENTAL"},{"label":"GSP 301 Placebo NS","type":"PLACEBO_COMPARATOR"}],"summary":"Study to evaluate the efficacy, safety and tolerability of GSP 301 nasal spray (NS) compared with placebo NS in pediatric subjects (aged 6 to under 12 years) with Seasonal Allergic Rhinitis (SAR).","primaryOutcome":{"measure":"Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score ( rTNSS) Over the 14-day Treatment Period","timeFrame":"Baseline and day 14","effectByArm":[{"arm":"GSP 301 NS","deltaMin":8.83,"sd":1.41},{"arm":"Placebo NS","deltaMin":8.84,"sd":1.66}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":32,"countries":["United States"]},"refs":{"pmids":["35926824"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":225},"commonTop":[]}}